Anyone used 3bp (3-bromopyruvate)?

5123 Posts | Page(s): Prev 12...506 507 508 509 510 ...512513 Next 

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Wed May 29, 2019 02:44 PM

Quote | Reply

Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma [1].

Also, DCA plus salinomycin [2] and 2-DG with salinomycin [3].

Refs:

1 https://www.nature.com/articles/s42003-019-0455-x

2 https://www.nature.com/articles/s41598-018-35815-4 

3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496345/

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Mon Jun 03, 2019 02:35 AM

Quote | Reply

This is so super exciting waiting and watching for the next step in metabolic medicine! Adding in one extra combo or in some way changing the route of administration or timing of dosing etc. could dramatically amplify metabolic responses.

We saw this with the melanoma patient when they added paracetamol to 3-BP. The patients's truly extreme tumor burden almost immediately shut down metabolic activity. That was one of the most massive tumor responses that I have read about.

It is not overly difficult to understand why there have been so many science fair entries; bachelor, master and PhD level research papers posted online; etc. including 3-BP when you consider the possibility that that one next step from 3-BP could give a breakthrough result. 3-BP alone gets you on to base. Finding another relevant pathway for a second hit, basically could make it a home run.    

critic, your DON and KD article is one such example. We have heard about this for quite some time on online videos. Now that it is finally officially published, it is nonetheless quite impressive. This should give the heads up to those on thread that there are a range of combos within our proximal imagination that would probably have largish anti-cancer effects.

Here's another one that while somewhat beyond my reach should have been within my grasp.

https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article

This one might substantially amp up 3-BP and other metabolic approaches. The melanoma patient's 3-BP treatment was dramatically enhanced with paracetamol. Yet, as the article cited above noted, there are actually two parallel escape routes available to counter-act 3-BP- glutathione and thioredoxin.

Paracetamol took care of the glutathione pathway. Article notes that auranofin can take out thioredoxin. This is startling. It has taken about 5 years to move the ball ahead on this point, though now basically it might be in reach to essentially block out a central anti-3-BP mechanism. This potentially could magnify 3-BP effectiveness for a range of patients. 

We desperately need clinical trials of 3-BP to investigate the safety and possible efficacy of a range of 3-BP combos. Shutting down the defences against 3-BP, certainly could be a powerful anti-cancer treatment, though it would be reassuring if evidence could be published establishing that this was in fact safe. 

Would also love to see nanoformulations of paracetamol, auranofin, BSO etc.. Targetting these medications directly to cancer cells and then treating with 3-BP might offer very profound anti-cancer effects with few if any side effects. 

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Fri Jun 07, 2019 09:22 PM

Quote | Reply

Some more data on SM-88 will be presented [1]. The median overall survival in patients' who have failed two prior lines of therapy is just 1-2.5 months. Two other trials (monotherapy in 2nd line and combined with chemo in 1st line) are planned.

A nasal version for brain/glioma, injectable for digestively compromised, intratumoral and new oral based one are all at the development stage.

Ref:

1 https://www.globenewswire.com/news-release/2019/06/07/186583

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Wed Jun 12, 2019 09:02 PM

Quote | Reply

On May 26, 2019 12:16 AM dumbcritic wrote:

On Apr 09, 2019 11:03 PM dumbcritic wrote:

The trial (NCT01976585) testing this in low-grade lymphoma is still recruiting. Another (NCT03789097) is open to patients with either NHL, metastatic breast or head and neck squamous cell carcinoma and adds Keytruda.

https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc er-vaccine-factories.html "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc "" target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc target="_blank" rel="nofollow">https://medicalxpress.com/news/2019-04-treatment-tumors-canc

JohnnyP, here are links to two other trials which may be of help to your wife [1,2].

Refs:

https://clinicaltrials.gov/ct2/show/NCT03412877 "" target="_blank" rel="nofollow">https://clinicaltrials.gov/ct2/show/NCT03412877 " target="_blank" rel="nofollow">https://clinicaltrials.gov/ct2/show/NCT03412877

https://clinicaltrials.gov/ct2/show/NCT01174121 "" target="_blank" rel="nofollow">https://clinicaltrials.gov/ct2/show/NCT01174121 " target="_blank" rel="nofollow">https://clinicaltrials.gov/ct2/show/NCT01174121

Another neoantigen trial in those with metastatic melanoma, UC, ovarian, CRC, breast or prostate cancer. Here is the link https://clinicaltrials.gov/ct2/show/NCT03970382

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Wed Jun 12, 2019 09:15 PM

Quote | Reply

On Jun 03, 2019 2:35 AM Jcancom wrote:

This is so super exciting waiting and watching for the next step in metabolic medicine! Adding in one extra combo or in some way changing the route of administration or timing of dosing etc. could dramatically amplify metabolic responses.

We saw this with the melanoma patient when they added paracetamol to 3-BP. The patients's truly extreme tumor burden almost immediately shut down metabolic activity. That was one of the most massive tumor responses that I have read about.

It is not overly difficult to understand why there have been so many science fair entries; bachelor, master and PhD level research papers posted online; etc. including 3-BP when you consider the possibility that that one next step from 3-BP could give a breakthrough result. 3-BP alone gets you on to base. Finding another relevant pathway for a second hit, basically could make it a home run.    

critic, your DON and KD article is one such example. We have heard about this for quite some time on online videos. Now that it is finally officially published, it is nonetheless quite impressive. This should give the heads up to those on thread that there are a range of combos within our proximal imagination that would probably have largish anti-cancer effects.

Here's another one that while somewhat beyond my reach should have been within my grasp.

https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article =8534&context=open_access_pubs"" target="_blank" rel="nofollow">https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article target="_blank" rel="nofollow">https://digitalcommons.wustl.edu/cgi/viewcontent.cgi?article

This one might substantially amp up 3-BP and other metabolic approaches. The melanoma patient's 3-BP treatment was dramatically enhanced with paracetamol. Yet, as the article cited above noted, there are actually two parallel escape routes available to counter-act 3-BP- glutathione and thioredoxin.

Paracetamol took care of the glutathione pathway. Article notes that auranofin can take out thioredoxin. This is startling. It has taken about 5 years to move the ball ahead on this point, though now basically it might be in reach to essentially block out a central anti-3-BP mechanism. This potentially could magnify 3-BP effectiveness for a range of patients. 

We desperately need clinical trials of 3-BP to investigate the safety and possible efficacy of a range of 3-BP combos. Shutting down the defences against 3-BP, certainly could be a powerful anti-cancer treatment, though it would be reassuring if evidence could be published establishing that this was in fact safe. 

Would also love to see nanoformulations of paracetamol, auranofin, BSO etc.. Targetting these medications directly to cancer cells and then treating with 3-BP might offer very profound anti-cancer effects with few if any side effects. 

Based on the fact the median overall survival in patients with rGBM is just 3-11/12 months, it's a shame the RKD plus DON doesn't get funding to be tested in a PhI trial. 

I think the data would be encouraging and this could lead to other trials testing the combo with hyperbaric oxygen, ketone supplements, the Optune device [1], perillyl alcohol, valganciclovir [2] and/or a few other therapies.

Refs:

1 https://www.optune.com/hcp/clinical-data/efficacy

2 https://www.nejm.org/doi/full/10.1056/NEJMc1302145

RE: Anyone used 3bp (3-bromopyruvate)?

by dumbcritic on Mon Jun 17, 2019 02:41 PM

Quote | Reply

Calithera Biosciences has reported positive results from its PhII ENTRATA trial of Telaglenastat (CB-839) in combination with Everolimus in patients with advanced RCC.

The primary endpoint of the trial was PFS and the secondary endpoint was overall survival which is not yet mature.

The combination doubled the median progression-free survival  in heavily pre-treated patients to 3.8 months as compared to 1.9 months for Everolimus alone and reduced the risk of disease progression or death by 36%. It also had a well-tolerated safety profile.

RE: Anyone used 3bp (3-bromopyruvate)?

by Jcancom on Tue Jun 18, 2019 12:44 AM

Quote | Reply

Yes, critic, it surprises me as well that metabolic medicine continues to be at the periphery. When JohnnyP started mentioning the various chemotherapies I was at such a complete loss. Once the cancer resists then what?

There have been some dramatic responses with some of the new class of pharmaceuticals (such as BRAF), and then there is resistance and then it's back to square one.

Metabolic medicine offers a nearly endless list of treatments that could target the main pathways. I have wanted to help D make a glyco list on his forum for quite some time, though even with the main branch glyco inhibitors there is a great deal of them.

The types of clinical trials that we would like to see including a complex, multifaceted combination of various possible anti-metabolics might never happen. We are then left with monotherapy results that would be expected to be negative, though not highly informative.

Yes, perillyl alcohol that is one that is in the background for us. The POH-3-BP formulation might be shockingly effective. I am anxious to hear of more results for this.

Here's another one that looks quite exciting!

https://news.harvard.edu/gazette/story/2019/05/mass-general-

 

RE: Anyone used 3bp (3-bromopyruvate)?

by JohnnyP on Wed Jun 19, 2019 01:38 PM

Quote | Reply

Shirley entering the HBOT chamber last week.  I goofed and started the video in portrait mode, so everything is sideways.

https://www.youtube.com/watch?v=FtC-QEbUq88

Looking pretty good for 78 with terminal cancer.  :)

Her 20th session will be next Monday, then we'll get a blood test to see if the CA15-3 marker has improved, then a PET scan in a few months.

Nevertheless, we will be signing up for 20 more sessions right away, this time for 90 minutes.  That's 120 minutes total time in the chamber.  advancedhyperbarics.com .

RE: Anyone used 3bp (3-bromopyruvate)?

by Danielus on Wed Jun 19, 2019 03:03 PM

Quote | Reply

Building on your statement --> There are at least 3 patinets I am aware of each doing better than expected following the use of these combos:

1. glioblastoma patinet using RKD and glu targeting and 2DG and Salinomycin (and several other repurposed drugs) - alive and well while she was les an less good while only on TMZ and before implementing these 

2. breast cancer patinet with liver mets using DCA and Salinomycin - alive for much longer time frame than expected

3. maxilary cancer with mets in many places and cachexia (40kg weight) using 2DG and Sal - some tumors shrinking others totally gone - the challenge its the low weight that remained the same during the nearly one year long treatment with Sal and 2DG metronomic

RE: Anyone used 3bp (3-bromopyruvate)?

by Danielus on Wed Jun 19, 2019 03:07 PM

Quote | Reply

On May 29, 2019 2:44 PM dumbcritic wrote:

Therapeutic benefit of combining calorie-restricted ketogenic diet and glutamine targeting in late-stage experimental glioblastoma [1].

Also, DCA plus salinomycin [2] and 2-DG with salinomycin [3].

Refs:

1 https://www.nature.com/articles/s42003-019-0455-x "" target="_blank" rel="nofollow">https://www.nature.com/articles/s42003-019-0455-x " target="_blank" rel="nofollow">https://www.nature.com/articles/s42003-019-0455-x

2 https://www.nature.com/articles/s41598-018-35815-4  "" target="_blank" rel="nofollow">https://www.nature.com/articles/s41598-018-35815-4  " target="_blank" rel="nofollow">https://www.nature.com/articles/s41598-018-35815-4 

3 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496345/ "" target="_blank" rel="nofollow">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496345/ " target="_blank" rel="nofollow">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496345/

Building on your statement --> There are at least 3 patinets I am aware of each doing better than expected following the use of these combos:

1. glioblastoma patinet using RKD and glu targeting and 2DG and Salinomycin (and several other repurposed drugs) - alive and well while she was les an less good while only on TMZ and before implementing these 

2. breast cancer patinet with liver mets using DCA and Salinomycin - alive for much longer time frame than expected

3. maxilary cancer with mets in many places and cachexia (40kg weight) using 2DG and Sal - some tumors shrinking others totally gone - the challenge its the low weight that remained the same during the nearly one year long treatment with Sal and 2DG metronomic

5123 Posts | Page(s): Prev 12...506 507 508 509 510 ...512513 Next 
Subscribe to this message board discussion

Latest Messages

View More

We care about your feedback. Let us know how we can improve your CancerCompass experience.